Scott recently retired from Johnson & Johnson after almost 30 years in the pharmaceutical industry. He began his pharmaceutical career in Drug Discovery with Wyeth in the Women’s Health Research Institute and later moved to Johnson & Johnson in 2001 when he joined as Head of the Reproductive Therapeutic Drug Discovery Team. In that role, he was responsible for leading the Discovery Research, and later added the Early Clinical Development pipeline, in the area of Reproductive Medicine and Urology.
Scott moved from Drug Discovery and Development into Business Development and spent the last 17+ years as a member of the Johnson & Johnson Innovative Medicine Business Development (IMBD) team, most recently on the Acquisitions and Divestitures (A&D) team. Prior to his A&D role, Scott spent more than 15 years in Search and Evaluation, supporting the Cardiovascular, Metabolism and Retina Therapeutic Areas (TA). In addition, he served as Alliance Manager for several of the partnerships for the TA. During his tenure in IMBD, Scott led assessments of external opportunities from initial strategy development and asset identification through due diligence and contributed to the contract negotiations. During his time in BD, he executed deals for programs from all stages of discovery and development (target identification through Phase 3), and across all modalities (small molecules, peptides, antibodies, nucleic acids, cell therapies, gene therapies, etc.).
Scott’s obtained his B.S. from Central Michigan University and his M.S. and Ph.D. from the University of Illinois-Urbana/Champaign. He was the recipient of an American Cancer Society Fellowship for his postdoctoral training at the University of Wisconsin-Madison, in the laboratory of Dr. Jack Gorski.